Supply chain disruptions forced 60% of rheumatologists to replace drugs

November 03, 2022

2 minute read


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

Supply chain disruptions have forced nearly two-thirds of rheumatologists to substitute drugs for their patients, according to survey results released by Cardinal Health.

In its new report, Cardinal Health said factors such as supply chain disruptions and FDA warning labels have played a role in changing how rheumatologists approach treatment decisions. . In one of its findings, the report states that 60% of rheumatologists surveyed said they needed to replace patient medications due to supply chain disruptions.

Supply Chain Disruption Chart

Supply chain disruptions have forced nearly two-thirds of rheumatologists to substitute drugs for their patients, according to survey results released by Cardinal Health.

“Rheumatologists deal with many complex issues beyond their control,” Rock Siavelis, the senior vice president and general manager of healthcare system and provider distribution at Cardinal Health, said in the report. “Supply chain disruptions and shortages of essential therapies have affected almost every area of ​​healthcare, forcing doctors to switch patients to different drugs or delay therapy altogether.”

In addition to supply chain changes and disruptions, the FDA’s black box warning on Janus kinase inhibitors has reduced the percentage of rheumatologists who report being willing to prescribe this class of drugs to patients.

Following the addition of a black box to JAK inhibitors, 72% of rheumatologists said they “very likely” or “probably” prescribe these drugs to their patients, compared to 78% of rheumatologists who said they “very likely” prescribe these drugs. often” Janus kinase inhibitors. or “often” before the warning is added.

“Overall, our survey shows that rheumatologists quickly adapted to changes beyond their control,” Gordon K. Lam, MD, FACR, the medical director of clinical research at Arthritis and Osteoporosis Consultants of the Carolinas, wrote in the report. “As the dynamic continues to change, it will be interesting to see how they respond to other challenges.”

According to Cardinal Health, the online surveys were conducted with more than 100 rheumatologists in community and hospital practices from July through September.

The report further recognizes greater ease of use with biosimilars. According to the survey, 76% of rheumatologists are “very familiar” with biosimilars, up from 53% in the 2020 survey. Additionally, 94% of rheumatologists are “very” or “somewhat” comfortable prescribing biosimilars, compared to 90% in 2020.

“Our 2022 survey shows a remarkable increase in familiarity and comfort in prescribing biosimilars compared to 2020,” Sonia OskoueiPharmD, BCMAS, DPLA, the vice president of biosimilars at Cardinal Health, said in the report. “This growth in both familiarity and comfort in prescribing follows trends seen in other therapeutic areas as the adoption of biosimilars increases over time.”

About Michael Bill

Check Also

Miracle Diabetes Curing Diet Nets Biggest Deal in Shark Tank History!

() – It was the most watched episode in Shark Tank history when sisters Anna …